Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin

被引:36
作者
Ma, Jun Li [1 ]
Zeng, Shan [1 ]
Zhang, Yan [1 ]
Deng, Gan Lu [1 ]
Shen, Hong [1 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
关键词
Hepatocellular carcinoma; Oxaliplatin; Drug resistance; Epithelial-mesenchymal transition; DOXORUBICIN; ESTABLISHMENT; CHEMOTHERAPY; CONTRIBUTES;
D O I
10.1007/s13277-015-4458-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drug resistance is one characteristic of hepatocellular carcinoma (HCC) and can affect the prognosis of patients directly. To explore drug resistance well, we established an oxaliplatin (OXA)-resistant cell line Bel-7402/OXA by exposure to gradually increased concentration of OXA. Some biological characters, such as proliferation, migration, and invasion, were studied. Drug sensitivity and the mechanisms of drug resistance were also investigated. We found that the resistant index of Bel-7402/OXA was 8.3. In comparison with Bel-7402, the percentages of cells in S and G2/M phase were increased. The nature apoptosis rate and drug-after apoptosis rate were all decreased in Bel-7402/OXA, as compared to Bel-7402. Bel-7402/OXA acquired increased migration and invasion ability with epithelial-mesenchymal transition (EMT) phenotype. Knockdown of EMT transcription factor Snail could reverse EMT and sensitized Bel-7402/OXA cells to OXA. EMT was one mechanism of drug resistance and may be a novel target of treatment for drug resistance.
引用
收藏
页码:6177 / 6184
页数:8
相关论文
共 17 条
[1]  
[Anonymous], GASTRIC CANC
[2]   Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer [J].
Arumugam, Thiruvengadam ;
Ramachandran, Vijaya ;
Fournier, Keith F. ;
Wang, Huamin ;
Marquis, Lauren ;
Abbruzzese, James L. ;
Gallick, Gary E. ;
Logsdon, Craig D. ;
McConkey, David J. ;
Choi, Woonyoung .
CANCER RESEARCH, 2009, 69 (14) :5820-5828
[3]   The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance [J].
Chow, Ariel Ka-Man ;
Ng, Lui ;
Lam, Colin Siu-Chi ;
Wong, Sunny Kit-Man ;
Wan, Timothy Ming-Hun ;
Cheng, Nathan Shiu-Man ;
Yau, Thomas Chung-Cheung ;
Poon, Ronnie Tung-Ping ;
Pang, Roberta Wen-Chi .
PLOS ONE, 2013, 8 (11)
[4]   Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients [J].
Coriat, Romain ;
Mir, Olivier ;
Cessot, Anatole ;
Brezault, Catherine ;
Ropert, Stanislas ;
Durand, Jean-Philippe ;
Cacheux, Wulfran ;
Chaussade, Stanislas ;
Goldwasser, Francois .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) :376-381
[5]   FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive? [J].
Liccioni, Alexandre ;
Reig, Maria ;
Bruix, Jordi .
JOURNAL OF HEPATOLOGY, 2014, 61 (01) :164-165
[6]   Oxaliplatin-based Chemotherapy: A New Option in Advanced Hepatocellular Carcinoma. A Systematic Review and Pooled Analysis [J].
Petrelli, F. ;
Coinu, A. ;
Borgonovo, K. ;
Cabiddu, M. ;
Ghilardi, M. ;
Lonati, V. ;
Barni, S. .
CLINICAL ONCOLOGY, 2014, 26 (08) :488-496
[7]   Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study [J].
Qin, Shukui ;
Cheng, Ying ;
Liang, Jun ;
Shen, Lin ;
Bai, Yuxian ;
Li, Jianfeng ;
Fan, Jia ;
Liang, Luian ;
Zhang, Yaqi ;
wu, Gang ;
Rau, Kun-Ming ;
Yang, Tsai-Shen ;
Jian, Zhixiang ;
Liang, Houjie ;
Sun, Yan .
ONCOLOGIST, 2014, 19 (11) :1169-1178
[8]   Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia [J].
Qin, Shukui ;
Bai, Yuxian ;
Lim, Ho Yeong ;
Thongprasert, Sumitra ;
Chao, Yee ;
Fan, Jia ;
Yang, Tsai-Shen ;
Bhudhisawasdi, Vajarabhongsa ;
Kang, Won Ki ;
Zhou, Yu ;
Lee, Jee Hyun ;
Sun, Yan .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) :3501-+
[9]   Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters [J].
Saxena, M. ;
Stephens, M. A. ;
Pathak, H. ;
Rangarajan, A. .
CELL DEATH & DISEASE, 2011, 2 :e179-e179
[10]   Cancer Statistics, 2014 [J].
Siegel, Rebecca ;
Ma, Jiemin ;
Zou, Zhaohui ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (01) :9-29